



Supplementary Figure 1 Geographical distribution of publications on transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), 2012–2021.

B

2012

2013

2016

2019

2021



#1 drug-eluting bead

#2 ablation

#3 cone-beam computed tomography

#4 hepatic arterial infusion

#5 hepatocellular carcinoma

#6 targeted therapy

#7 response assessment

#8 radioembolization

C Top 20 Keywords with the Strongest Citation Bursts

Keywords	Year	Strength	Begin	End	2012 - 2021
randomized controlled trial	2012	40.08	2012	2014	
cirrhosis	2012	21.14	2012	2014	
lipiodol chemoembolization	2012	15.68	2012	2014	
percutaneous ethanol injection	2012	10.82	2012	2014	
united states	2012	9.63	2012	2014	
iodized oil	2012	9.25	2012	2013	
y 90 microsphere	2012	8.18	2012	2014	
interventional oncology	2012	7.92	2012	2015	
waiting list	2012	7.22	2012	2015	
local radiotherapy	2012	6.55	2012	2015	
10 cm	2012	5.96	2014	2015	
transarterial embolization	2012	6.43	2015	2018	
vein tumor thrombus	2012	5.82	2016	2018	
clinical practice guideline	2012	11.31	2017	2021	
milan criteria	2012	8.11	2017	2018	
survival benefit	2012	6.55	2018	2021	
diagnosis	2012	8.71	2019	2021	
stage	2012	7.64	2019	2021	
therapeutic chemoembolization	2012	7.63	2019	2021	
propensity score matching	2012	6.94	2019	2021	

Supplementary Figure 2 Mapping based on co-cited keywords from transarterial chemoembolization (TACE) treatment for hepatocellular carcinoma (HCC) research. A: A network diagram of co-cited keywords. Using different colour, 192 terms that appeared more than 20 times were separated into five clusters. The size of the nodes indicates occurrence frequency; B: Timeline distribution of keyword cluster analysis; C: The top 20 co-cited keywords with the most citation burstiness. Years between “Begin” and “End” represent the period when the keywords were more influential. Years in light green mean that the keywords have not

appeared, years in dark green mean that the keywords are less influential, and years in red mean that the keywords are more influential.

Supplementary Table 1 The primary topics covered within the 10 most cited articles

Rank	Title	DOI number	Predicti	Combin	Clinci	Basic
1	Global patterns of hepatocellular carcinoma management from diagnosis to death: the	10.1111/liv.12818	×	×	√	×
2	Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced	10.1200/JCO.2012.44.1659	×	√	√	×
3	Development of Hong Kong Liver Cancer staging system with treatment stratification for	10.1053/j.gastro.2014.02.032	√	×	√	×
4	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate	10.1016/j.jhep.2016.01.012	×	√	√	×
5	Recurrence of hepatocellular cancer after	10.1097/SLA.00000000000000710	×	×	√	×
6	Radiofrequency ablation with or without	10.1200/JCO.2012.42.9926	×	√	√	×
7	Survival of patients with hepatocellular carcinoma treated by transarterial	10.1016/j.jhep.2012.01.008	×	×	√	×
8	Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular	10.1016/j.jhep.2017.06.026	×	×	√	×

9	Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With	10.1053/j.gastro.2016.08	×	×	√	×
10	Hepatic resection associated with good survival for selected patients with	10.1097/SLA.0000000000	×	×	√	×
